Volastra Therapeutics

Biotechnology ResearchNew York, United States11-50 Employees

Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline.  Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1  clinical trials for cancers with high levels of chromosomal instability.

Sign up for free to view info Email Format Employee directory